CLTC
CLTC (Clathrin heavy chain 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.
Overview
Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Two different adapter protein complexes link the clathrin lattice either to the plasma membrane or to the trans-Golgi network. Acts as a component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilisation of kinetochore fibres of the mitotic spindle by acting as inter-microtubule bridge.
Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.84, affected pathway 0.94, genetic association 0.00, somatic mutation 0.85). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cholangiocarcinoma, Hepatocellular Carcinoma, Upper Tract Urothelial Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CLTC (Clathrin heavy chain 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.
- 1 · What it is
CLTC (Clathrin heavy chain 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.
- 2 · What goes wrong in cancer
Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Two different adapter protein complexes link the clathrin lattice either to the plasma membrane or to the trans-Golgi network.
- 3 · How drugs use it
No product in this corpus aims at CLTC yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:2092 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q00610 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000141367 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.51, melanoma 0.51, non-Hodgkin lymphoma 0.53, breast cancer 0.55, lung cancer 0.53 (GraphQL API, CC0)); IntOGen CLTC (driver in 5 cohorts (Act 3, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Two different adapter protein complexes link the clathrin lattice either to the plasma membrane or to the trans-Golgi network. Acts as a component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilisation of kinetochore fibres of the mitotic spindle by acting as inter-microtubule bridge. The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fibre tension. Plays a role in early autophagosome formation. Interaction with DNAJC6 mediates the recruitment of HSPA8 to the clathrin lattice and creates local destabilisation of the lattice promoting uncoating. Location: Cytoplasmic vesicle membrane; Membrane, coated pit; Melanosome; Cytoplasm, cytoskeleton, spindle (UniProt). Locus 17q23.1 (HGNC).
- Breast cancer: Open Targets association 0.55 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (UTUC)
- Non-Hodgkin lymphoma: Open Targets association 0.53 with non-Hodgkin lymphoma (MONDO_0018908)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CLTC" OR ABSTRACT:"CLTC" OR TITLE:"clathrin heavy chain" OR ABSTRACT:"clathrin heavy chain" OR TITLE:"Clathrin heavy chain 1" OR ABSTRACT:"Clathrin heavy chain 1" OR TITLE:"Hc" OR ABSTRACT:"Hc" OR TITLE:"CLTCL2" OR ABSTRACT:"CLTCL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CLTC, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetRANBP2
Shares Clear cell renal cell carcinoma, Lung cancer (all types), Renal cell carcinoma, Hepatocellular carcinoma.
- TargetARHGEF12
Shares Clear cell renal cell carcinoma, Lung cancer (all types), Renal cell carcinoma, Breast cancer (all types).
- TargetPTPRK
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Bladder & urothelial cancer, Breast cancer (all types).
- TargetZNF429
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, Hepatocellular carcinoma, IntOGen.
- TargetARID1A
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer, Hepatocellular carcinoma.
- TargetCACNA1D
Shares Lung cancer (all types), Renal cell carcinoma, Hepatocellular carcinoma, Breast cancer (all types).
- TargetRAP1GDS1
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Breast cancer (all types), IntOGen.
- TargetTP63
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer, Breast cancer (all types).